• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基线CD4＜50个细胞/立方毫米与CD4≥50个细胞/立方毫米的HIV感染患者之间，司他夫定、拉米夫定和奈韦拉平抗逆转录病毒疗法通用固定剂量组合的安全性和疗效。

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.

作者信息

Manosuthi Weerawat, Chimsuntorn Sukanya, Likanonsakul Sirirat, Sungkanuparph Somnuek

机构信息

Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand.

出版信息

AIDS Res Ther. 2007 Mar 13;4:6. doi: 10.1186/1742-6405-4-6.

DOI:10.1186/1742-6405-4-6
PMID:17352834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1828738/
Abstract

BACKGROUND

Antiretroviral therapy (ART) with a generic fixed-dose combination (FDC) of stavudine (d4T)/lamivudine (3TC)/nevirapine (NVP) is widely used in developing countries. The clinical data of this FDC among very advanced HIV-infected patients is limited.

METHODS

A retrospective cohort study was conducted among ART-naïve HIV-infected patients who were initiated a generic FDC of d4T/3TC/NVP between May 2004 and October 2005. Patients were categorized into 2 groups according to the baseline CD4 (group A: <50 cell/mm3 and group B: > or = 50 cell/mm3).

RESULTS

There were 204 patients with a mean +/- SD age of 37.1 +/- 8.9 years, 120 (58.8%) in group A and 84 (41.2%) in group B. Median (IQR) CD4 cell count was 6 (16-29) cells/mm3 in group A and 139 (92-198) cells/mm3 in group B. Intention-to-treat analysis at 48 weeks, 71.7% (86/120) of group A and 75.0% (63/84) of group B achieved plasma HIV RNA <50 copies/ml (P = 0.633). On-treatment analysis, 90.5% (87/96) in group A and 96.9% (63/65) in group B achieved plasma HIV RNA <50 copies/ml (P = 0.206). At 12, 24, 36 and 48 weeks of ART, mean CD4 were 98, 142, 176 and 201 cells/mm3 in group A and 247, 301, 336 and 367 cells/mm3 in group B, respectively. There were no differences of probabilities to achieve HIV RNA <50 copies/ml (P = 0.947) and CD4 increment at 48 weeks between the two groups (P = 0.870). Seven (9.6%) patients in group A and 4 (8.5%) patients in group B developed skin reactions grade II or III (P = 1.000). ALT at 12 weeks was not different from that at baseline in both groups (P > 0.05).

CONCLUSION

Initiation of FDC of d4T/3TC/NVP in HIV-infected patients with CD4 <50 and > or = 50 cells/mm3 has no different outcomes in terms of safety and efficacy. FDC of d4T/3TC/NVP can be effectively used in advance HIV-infected patients with CD4 <50 cells/mm3.

摘要

背景

由司他夫定（d4T）/拉米夫定（3TC）/奈韦拉平（NVP）组成的通用型固定剂量复方（FDC）抗逆转录病毒疗法（ART）在发展中国家广泛应用。该FDC在极晚期HIV感染患者中的临床数据有限。

方法

对2004年5月至2005年10月间开始使用d4T/3TC/NVP通用型FDC的初治HIV感染患者进行回顾性队列研究。根据基线CD4水平将患者分为两组（A组：<50个细胞/mm3，B组：≥50个细胞/mm3）。

结果

共204例患者，平均年龄为37.1±8.9岁，A组120例（58.8%），B组84例（41.2%）。A组CD4细胞计数中位数（IQR）为6（16 - 29）个细胞/mm3，B组为139（92 - 198）个细胞/mm3。48周意向性分析时，A组71.7%（86/120）和B组75.0%（63/84）的血浆HIV RNA<50拷贝/ml（P = 0.633）。治疗中分析时，A组90.5%（87/96）和B组96.9%（63/65）的血浆HIV RNA<50拷贝/ml（P = 0.206）。在ART的12、24、36和48周时，A组平均CD4分别为98、142、176和201个细胞/mm3，B组分别为247、301、336和367个细胞/mm3。两组在48周时实现HIV RNA<50拷贝/ml的概率（P = 0.947）和CD4增加量（P = 0.870）无差异。A组7例（9.6%）和B组4例（8.5%）患者发生II级或III级皮肤反应（P = 1.000）。两组12周时的ALT与基线时无差异（P>0.05）。

结论

对于CD4<50和≥50个细胞/mm3的HIV感染患者，起始使用d4T/3TC/NVP FDC在安全性和疗效方面无差异。d4T/3TC/NVP FDC可有效用于CD4<50个细胞/mm3的晚期HIV感染患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21a0/1828738/50a2b259a39f/1742-6405-4-6-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21a0/1828738/5d0ca426d525/1742-6405-4-6-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21a0/1828738/50a2b259a39f/1742-6405-4-6-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21a0/1828738/5d0ca426d525/1742-6405-4-6-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21a0/1828738/50a2b259a39f/1742-6405-4-6-2.jpg

相似文献

1
Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.基线CD4＜50个细胞/立方毫米与CD4≥50个细胞/立方毫米的HIV感染患者之间，司他夫定、拉米夫定和奈韦拉平抗逆转录病毒疗法通用固定剂量组合的安全性和疗效。
AIDS Res Ther. 2007 Mar 13;4:6. doi: 10.1186/1742-6405-4-6.
2
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.司他夫定、拉米夫定和奈韦拉平简化固定剂量组合（GPO-VIR）治疗晚期HIV感染患者的安全性和有效性：一项为期24周的研究。
J Med Assoc Thai. 2004 Jul;87(7):760-7.
3
Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.泰国未接受过抗逆转录病毒治疗的晚期HIV感染初治患者使用司他夫定、拉米夫定和奈韦拉平通用固定剂量组合96周后的疗效及代谢并发症：一项前瞻性研究
Curr Ther Res Clin Exp. 2008 Feb;69(1):90-100. doi: 10.1016/j.curtheres.2008.02.007.
4
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.一项随机、开放标签、比较性试验，旨在评估三种抗逆转录病毒药物组合（包括两种核苷类似物和奈韦拉平）用于既往未接受治疗的HIV-1感染的疗效和安全性：OzCombo 2研究。
HIV Clin Trials. 2002 May-Jun;3(3):177-85. doi: 10.1310/9n21-1hg1-7n1q-jkw1.
5
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.通用抗逆转录病毒药物的现场评估：喀麦隆的一项前瞻性队列研究。
Antivir Ther. 2005;10(2):335-41.
6
Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.在接受司他夫定、拉米夫定和奈韦拉平固定剂量复方初始治疗方案失败的HIV-1感染患者中，K65R突变的发生率及危险因素。
J Clin Virol. 2008 Apr;41(4):310-3. doi: 10.1016/j.jcv.2007.12.015. Epub 2008 Mar 7.
7
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).在未接受过抗逆转录病毒治疗的HIV感染者中，司他夫定加拉米夫定与齐多夫定加拉米夫定联合茚地那韦的比较：胸腺嘧啶核苷类似物治疗方案的选择（START I）
AIDS. 2000 Jul 28;14(11):1591-600. doi: 10.1097/00002030-200007280-00015.
8
An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.齐多夫定加拉米夫定与司他夫定加拉米夫定的开放性随机对照试验。
AIDS. 1998 Aug 20;12(12):1513-9. doi: 10.1097/00002030-199812000-00014.
9
Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.泰国HIV感染患者中司他夫定、拉米夫定和奈韦拉平固定剂量复方制剂（GPO-VIR）的血浆奈韦拉平水平及24周疗效
J Med Assoc Thai. 2007 Feb;90(2):244-50.
10
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.司他夫定、拉米夫定和奈韦拉平通用固定剂量复方制剂（GPO-vir）治疗晚期HIV感染的疗效与安全性
J Med Assoc Thai. 2006 Sep;89(9):1472-8.

引用本文的文献

1
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.在病毒学抑制的HIV感染患者中从品牌抗逆转录病毒药物转换为仿制药的疗效和安全性。
PLoS One. 2017 Aug 1;12(8):e0182007. doi: 10.1371/journal.pone.0182007. eCollection 2017.
2
Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.2014 年泰国成人和青少年 HIV-1 感染者抗逆转录病毒治疗指南。
AIDS Res Ther. 2015 Apr 24;12:12. doi: 10.1186/s12981-015-0053-z. eCollection 2015.
3
Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.

本文引用的文献

1
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.成人HIV感染的治疗：美国国际艾滋病协会专家组2006年建议
JAMA. 2006 Aug 16;296(7):827-43. doi: 10.1001/jama.296.7.827.
2
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.接受含奈韦拉平的高效抗逆转录病毒治疗（无论是否联用利福平）的HIV感染患者的血浆奈韦拉平水平及24周疗效
Clin Infect Dis. 2006 Jul 15;43(2):253-5. doi: 10.1086/505210. Epub 2006 Jun 12.
3
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
泰国未接受过抗逆转录病毒治疗的晚期HIV感染初治患者使用司他夫定、拉米夫定和奈韦拉平通用固定剂量组合96周后的疗效及代谢并发症：一项前瞻性研究
Curr Ther Res Clin Exp. 2008 Feb;69(1):90-100. doi: 10.1016/j.curtheres.2008.02.007.
4
Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.赞比亚卢萨卡初级卫生保健环境中一线抗逆转录病毒方案的通用药物和专利药物的疗效：一项队列研究。
Int J Epidemiol. 2012 Apr;41(2):448-59. doi: 10.1093/ije/dys022.
资源匮乏地区的通用固定剂量复方抗逆转录病毒治疗：多中心观察性队列研究
AIDS. 2006 May 12;20(8):1163-9. doi: 10.1097/01.aids.0000226957.79847.d6.
4
Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.在一个加勒比发展中国家的非临床试验环境中，对高效抗逆转录病毒疗法的免疫和病毒学反应。
HIV Med. 2006 Mar;7(2):99-104. doi: 10.1111/j.1468-1293.2006.00347.x.
5
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).英国艾滋病协会（BHIVA）关于使用抗逆转录病毒疗法治疗HIV感染成人的指南（2005年）。
HIV Med. 2005 Jul;6 Suppl 2:1-61. doi: 10.1111/j.1468-1293.2005.0311b.x.
6
The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.GPO-VIR（司他夫定+拉米夫定+奈韦拉平）在初治成年HIV患者中的疗效及不良反应。
Southeast Asian J Trop Med Public Health. 2005 Mar;36(2):362-9.
7
Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability.在资源有限的环境中，对CD4细胞计数<50个/mm³的晚期艾滋病患者启动高效抗逆转录病毒治疗：疗效和耐受性。
Int J STD AIDS. 2005 Mar;16(3):243-6. doi: 10.1258/0956462053420121.
8
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.在感染HIV的受试者中使用奈韦拉平所导致的严重肝毒性。
J Infect Dis. 2005 Mar 15;191(6):825-9. doi: 10.1086/428093. Epub 2005 Feb 10.
9
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.随机接受奈韦拉平、依非韦伦或两种药物联合治疗方案的泰国患者皮疹的发生率及危险因素。
AIDS. 2005 Jan 28;19(2):185-92. doi: 10.1097/00002030-200501280-00011.
10
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.司他夫定、拉米夫定和奈韦拉平简化固定剂量组合（GPO-VIR）治疗晚期HIV感染患者的安全性和有效性：一项为期24周的研究。
J Med Assoc Thai. 2004 Jul;87(7):760-7.